Publisher
Springer International Publishing
Reference122 articles.
1. Anonymous. Anticholinergic therapies in the treatment of Parkinson’s disease. Mov Disord. 2002;17:S7–12.
2. Assal F, Spahr L, Hadengue A, Rubbia-Brandt L, Burkhard PR. Tolcapone and fulminant hepatitis. Lancet. 1998;352(9132):958.
3. Axelrod J, Tomchick R. Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem. 1958;233:702–5.
4. Baas H, Zehrden F, Selzer R, Kohnen R, Loetsch J, Harder S. Pharmacokinetic-pharmacodynamic relationship of levodopa with and without tolcapone in patients with Parkinson’s disease. Clin Pharmacokinet. 2001;40:383–93.
5. Barbeau A, Sourkes TL, Murphy GF. Les catecholamines dans la maladie de Parkinson. In: De Ajuriaguerra J, editor. Monoamines et système nerveux central. Paris: Masson; 1962. p. 247–62.